BIRMINGHAM, Ala., Jan. 2, 2017 /PRNewswire/ -- The pharmaceutical research company TPD LLC (Trends in Pharma Development) announced that the PanX® new class of medicines intended for the treatment of anxiety are now available nationwide as prescription compounded drugs.
Two US patents 9,446,030 and 9,517,231 were recently issued to the company in September and December, respectively. The patents broadly cover dual drug combinations of historically-safe active ingredients that are being re-purposed for the treatment of anxiety disorders, such as social anxiety disorder, panic, and PTSD. The combinations were designed to suppress the multiple symptoms of acute anxiety.
The PanX® drugs are intended as "as needed" alternatives to benzodiazepines (e.g., Xanax® or Valium®) that are addictive, have the potential for abuse, and are Controlled Substances. However, the active ingredients in the PanX® brand, beta blockers and antiemetic motion sickness agents, have no history of addiction or abuse in five decades of prescription or over-the-counter use. The company's goal for the patented new class of medicines is to provide effective, fast-acting, yet safer alternatives to benzodiazepines.
According to a leading authority on anxiety therapies, Professor Charles B. Nemeroff, MD PhD, Chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami, "A number of patients with prominent anxiety symptoms do not respond or cannot tolerate currently available treatments. This novel approach combining two medications with distinct mechanisms of action has the potential to fill an important niche in the management of such patients."
TPD has contracted with Pine Pharmaceuticals and Pine Pharmacy of New York, and Custom Meds of Florida to produce the products as prescription compounded drugs. The combination drug products are available in 49 states as patient-specific prescriptions by mail order and/or as "office use" medications administered by physicians, for instance in medical procedures when patients are anxious or fearful. For additional information see www.PanX.us.
TPD is also pursuing the clinical development of selected PanX® drugs to seek product approval by the US Food and Drug Administration (FDA).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alternatives-available-nationwide-to-addictive-benzodiazepines-for-anxiety-300384404.html
SOURCE TPD LLC